http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2672598-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd89f5703ce7b08c53ca4fb812949b20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2017-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d270b98eee570557a50e13ea739e1fae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67159e3f962e6af83f30b869f6df0def |
| publicationDate | 2018-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2672598-C1 |
| titleOfInvention | Method for predicting cholestatic hepatosis in pregnant women |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to therapy, gastroenterology, obstetrics, and concerns a method for predicting cholestatic hepatosis in pregnant women. Method includes: collecting complaints and conducting laboratory examination methods, characterized in that the presence and severity of pruritus, heartburn, the level of alanine aminotransferase, the level of alkaline phosphatase, the level of cholesterol are determined as the prognostic parameters. Next, each prognostic parameter is assigned a digital value determined by producing the corresponding cipher (n) and the classification function coefficient (k), whose value for the severity of pruritus is 0.826, for the presence of heartburn – 1.119, for the alanine aminotransferase level – 0.001, for the alkaline phosphatase level – 0.006, for the cholesterol level – 0.151, where in the absence of itchy skin n is 0, in localized itching of the skin n is 1, in diffuse itching of the skin n is 2, in the absence of heartburn n is 0, in the presence of heartburn, n is 1; for alanine aminotransferase, n is its level in U/l; for alkaline phosphatase, n is its level in U/l; for cholesterol, n is its value in mmol/l. Then, the obtained digital values are summed up with the addition of a constant to the sum obtained (-3.811), thus, the value of the prognostic factor is obtained, which is used to predict the presence of cholestatic hepatosis in a pregnant woman. Pregnant women with a positive value of the prognostic factor belong to the group with cholestatic hepatosis, and with its negative value – to the group without cholestatic hepatosis. n EFFECT: invention will improve the reliability, informativeness, ensure timely diagnosis of intrahepatic cholestasis of pregnant women and the appointment of a set of measures aimed at preventing complications of CGD, as well as facilitating the algorithmization and management of pregnant patients. n 1 cl, 14 tbl, 2 ex |
| priorityDate | 2017-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 82.